ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Consumer Discretionary / BYAH
BNKK (32) CABR (40) YCBD (36) UG (71) ⌘ Pro Terminal →

Park Ha Biological Technology Co. Ltd. (Class A) (BYAH) — RQD Stock Rating Cockpit

$1.92 -13.12% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.87

Park Ha Biological Technology Co. Ltd. (Class A) (BYAH) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • SELL / AVOID Cap $7.6M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BYAH Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BYAH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Park Ha Biological Technology Co. Ltd. (Class A) (NASDAQ: BYAH) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $1.92 (-13.12% 1D, market cap $7.6M). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 7/20. Across 1009 tracked Consumer Discretionary issuers, BYAH ranks #693 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BYAH compare to BNKK and CABR in the Consumer Discretionary sector?
▼

Within the Consumer Discretionary sector (Package Goods/Cosmetics), BYAH carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of 94.4%, and ROIC of —. By comparison, BNKK (Bonk Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $8.6M) and CABR (Caring Brands Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $11.8M). Among the 5-stock peer group, UG leads on earnings multiple (14.5x) while UG leads on capital efficiency (17.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BYAH?
▼

Per BYAH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-10-31, CIK 0001986247), Park Ha Biological Technology Co. Ltd. (Class A) generated $2.5M in revenue (+6.0% YoY), -$24.4M in net income, and $85.9K in free cash flow against $6.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Consumer Discretionary with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.87 (-2.55%)🧬 Dilution Drag (+1.36% YoY Shares)⚙️ Cash Engine: 14/20 (B-) • 3.4% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D-
025507510043
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- · Rk D
Cash (14)Whales (3)SEC (11)Macro (8)CEO (7)
Each axis scored 0–20
12M PRICE TARGET CONE-6.8% Base Target
$166 Bull$2 Base$1 Bear
📬 FREE BYAH RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BYAH)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (43/100 Composite)
🔍 WHY BYAH SCORES 43/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+14/20 pts (33% of score)

SEC XBRL FY 2025 (10-K): 3.4% FCF Margin ($85.9K FCF) & 94.4% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
51
Grade C-$2.37+0% Next Q
Q2 (-2Q)
48
Grade D$2.37-5.1% Next Q
Q3 (-1Q)
46
Grade D$2.25-14.7% Next Q
Current
43
Grade D-$1.92-6.7% Hist 90D α
Trajectory: C- (51) → D- (43)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BYAH Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BYAH currently carries a cautious 43/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Consumer Discretionary with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.46) and Max Pain ($2.02) forces dealer call-delta covering toward $165.90.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.36% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BYAH• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BYAH Beats Next Quarter EPS Consensus (Jan 29, 2027) & Holds Above 200D SMA”
YES 43%NO 57%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
43.130 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCORESOLID CORE (5–6)
5 / 99-Pt Accounting
52-WEEK LASER RANGE2% OF RANGE
L: $2$1.92H: $158
1. Money & Cash Health● MIXED
Are profits real cash in the bank?

Decent core business (94.4% gross margin), though cash flow growth is moderate rather than explosive right now.

Factor Grade: B-RQD 14 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 10 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 19 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

Quant Analyst Panel Split (Battleground) on BYAH

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BULLISH (70)

14.0% ROIC with 94.4% gross margin and 1.09% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
NEUTRAL (55)

Altman-Z 4.20 and Piotroski 5/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (30)

10/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like BYAH
  • ✓Established market leader in Consumer Discretionary with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BYAH)

  • ✓Walkthrough of BYAH's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
BYAH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -80.00%▲ RESISTANCE BREAKOUT
2026-11-03O $2.30H $2.30L $1.92C $1.92VOL 15.4K
RES: $0.68SUP: $1.56SMA50: $2.46SMA200: $10.24
$118.9$87.22$55.50$23.78$-7.94RES $0.68SUP $1.56$1.922026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BYAH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BYAH Butterfly Map → + Track BYAH →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on BYAH today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BYAH. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BYAH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BYAH)

Consumer Discretionary Rank #693 of 1009 ⚔️ BNKK vs BYAH Full Matrix →

1. Head-to-Head Consumer Discretionary Peer Comparison (BYAH vs. BNKK, CABR, YCBD, UG)

Industry: Package Goods/Cosmetics (23 Tracked Issuers)

Across 1009 tracked Consumer Discretionary securities in the Roarable RQD universe, Park Ha Biological Technology Co. Ltd. (Class A) (BYAH) ranks #693 by composite RQD confidence (43/100, grade D-) and #941 by equity capitalization ($7.6M). Within this direct 5-issuer industry benchmark cohort, UG leads on earnings valuation at 14.5x trailing P/E, while UG leads on capital efficiency and profitability with 17.8% ROIC and — gross margin. UG currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with BYAH at 43/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BYAH ACTIVE
Park Ha Biological Technology Co. Ltd. (Class A)
D- 43/100 — 94.4% — -13.12% $7.6M Benchmark Subject
BNKK
Bonk Inc.
E 32/100 — 58.5% -35.0% -1.85% $8.6M /bnkk-vs-byah →
CABR
Caring Brands Inc.
D- 40/100 — 55.6% -35.0% -7.96% $11.8M /cabr-vs-byah →
YCBD
cbdMD Inc.
D- 36/100 — 62.4% -30.4% +3.66% $4.3M /ycbd-vs-byah →
UG
United-Guardian Inc.
B- 71/100 14.5x — 17.8% +2.55% $32.5M /ug-vs-byah →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-10-31 • CIK 0001986247 ↗

In its most recent audited fiscal period (FY2025, filed 2025-10-31), Park Ha Biological Technology Co. Ltd. (Class A) (BYAH) reported GAAP revenue of $2.5M (+6.0% vs. FY2024 revenue of $2.4M , and +2.7% cumulative change since FY2023) , GAAP net income of -$24.4M, operating cash flow of $85.9K, and free cash flow of $85.9K (-91.1% YoY). On the balance sheet, BYAH closed FY2025 with $6.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-10-31 $2.5M -$24.4M $85.9K $85.9K $6.0M —
FY2024 (FY) 2024-10-31 $2.4M $478.6K $960.5K $960.5K — —
FY2023 (FY) 2023-10-31 $2.5M $852.0K $126.5K $126.5K — —

3. BYAH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BYAH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Park Ha Biological Technology Co. Ltd. (Class A) (NASDAQ: BYAH) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $1.92 (-13.12% 1D, market cap $7.6M). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 7/20. Across 1009 tracked Consumer Discretionary issuers, BYAH ranks #693 in composite RQD confidence.

How does BYAH compare to BNKK and CABR in the Consumer Discretionary sector?

Within the Consumer Discretionary sector (Package Goods/Cosmetics), BYAH carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of 94.4%, and ROIC of —. By comparison, BNKK (Bonk Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $8.6M) and CABR (Caring Brands Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $11.8M). Among the 5-stock peer group, UG leads on earnings multiple (14.5x) while UG leads on capital efficiency (17.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BYAH?

Per BYAH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-10-31, CIK 0001986247), Park Ha Biological Technology Co. Ltd. (Class A) generated $2.5M in revenue (+6.0% YoY), -$24.4M in net income, and $85.9K in free cash flow against $6.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Consumer Discretionary with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BYAH trading relative to its 50-day, 200-day, and 52-week technical levels?

BYAH last traded at $1.92 (-13.12% on volume of 35,620 shares), positioning the stock -21.95% below its 50-day simple moving average ($2.46) and -81.25% below its 200-day simple moving average ($10.24). Across its 52-week range of $1.90 to $158.00, BYAH sits at the 0.0% percentile with a 14-day RSI of 43.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.68 to $2.16).

Direct Sub-Reports: BYAH RQD Cockpit BYAH 12M Forecast BYAH Earnings & Move BYAH Dividends & DRIP BYAH Insiders & 13F BYAH Whale Options BYAH Profit Sankey BYAH News & Why
ROARABLE RATING BRIEF • RQD 43/100 (D-) ✓ SEC XBRL & RQD VERIFIED

BYAH — Park Ha Biological Technology Co. Ltd. (Class A): What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-10-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Park Ha Biological Technology Co. Ltd. (Class A) (BYAH) earns a live Roarable RQD composite score of 43/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $1.92 (-13.12% 1D, market capitalization $7.6M).

  • Fundamental Cash Engine (14/20): Anchored by return on invested capital (ROIC) of —, gross margin of 94.4%, operating margin of -60.0%, and free cash flow yield of 1.09%.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (7/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (11/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 5/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

. Ltd. (Class A) is a NASDAQ-listed issuer in the Consumer Discretionary sector and the Package Goods/Cosmetics industry. The profile identifies its market capitalization as $0.0B. Per the market data, gross margin is 94.4%, with operating margin at -60%.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-10-31), Park Ha Biological Technology Co. Ltd. (Class A) (BYAH) reported $2.5M in annual revenue (up from $2.4M in FY2024, +6.0% YoY) and -$24.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.5M revenue, $852.0K net income) through FY2025, BYAH scaled operating cash flow to $85.9K and free cash flow to $85.9K, backed by $6.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 43/100): Established market leader in Consumer Discretionary with deep daily trading liquidity. Free cash flow yield of 1.09% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 14/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.90 – $158.00 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No upstream or downstream dependencies, butterfly links, or proprietary signals are recorded. The source data therefore does not establish supplier concentration, customer dependency, or cross-sector correlation for BYAH. A prospective investor should note that the absence of mapped links means second-order effects cannot be evaluated from these sources. The only sector-level data point is the classification itself: Consumer Discretionary / Package Goods/Cosmetics.

  • Key Question #1: Can BYAH sustain or expand its -60.0% operating margin and — ROIC against Package Goods/Cosmetics peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $2.5M and free cash flow of $85.9K, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is BYAH's equity valuation to Consumer Discretionary capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

BYAH Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Park Ha Biological Technology Co. Ltd. (Class A) (BYAH) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BYAH Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BYAH Bull vs. Bear Conversation Board — What's Your Call at $1.92?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BYAH 🐻 33% BEARISH CONVICTION
1. Pick Your Side on BYAH:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $2.65 (+19.9%)
📌 Pinned Debate

Balance-sheet forensics score the strongest pillar at 11 / 20, with an Altman Z of 2.5 and a Debt/Equity of 0.5.

Long BYAH at $2.21 targeting $2.65. Balance-sheet forensics score the strongest pillar at 11 / 20, with an Altman Z of 2.5 and a Debt/Equity of 0.5.. Institutional whale score is 3/20 and the risk/reward vs. the $1.90 52-week low is skewed heavily in favor of bulls.

EarningsSniper 🐂 BULL

@BearTrap_Alert Shorting a 3/20 institutional whale-flow stock at $2.21 is dangerous when funds are rotating into Consumer Discretionary.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $1.66 (-24.9%)
Spot @ $2.21

Net income swung to -$24.4M in FY 2025 from positive results in FY 2023 and FY 2024, with ROIC at 0% and no institutional or insider co

I respect the product at Park Ha Biological Technology Co. Ltd. (Class A), but the stock at $2.21 is a different story. Net income swung to -$24.4M in FY 2025 from positive results in FY 2023 and FY 2024, with ROIC at 0% and no institutional or insider conviction support.. FCF yield is 1.09% and RQD sits at 43/100 (D-) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE